UBS Group Reiterates Neutral Rating for Novartis (NVS)

Novartis (NYSE:NVS)‘s stock had its “neutral” rating reiterated by UBS Group in a research report issued on Monday, www.boersen-zeitung.de reports.

NVS has been the subject of a number of other reports. Zacks Investment Research raised Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a research report on Tuesday, September 19th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, October 24th. Barclays downgraded Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th. Finally, Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Wednesday, December 27th. Five investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $85.32.

Shares of Novartis (NYSE:NVS) opened at $86.73 on Monday. The company has a current ratio of 1.08, a quick ratio of 0.81 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $227,090.00, a P/E ratio of 30.86, a P/E/G ratio of 2.32 and a beta of 0.74. Novartis has a 52-week low of $69.53 and a 52-week high of $87.29.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, beating the Zacks’ consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion during the quarter, compared to the consensus estimate of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. Novartis’s revenue was up 2.4% on a year-over-year basis. During the same period last year, the business posted $1.23 earnings per share. research analysts anticipate that Novartis will post 4.79 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cetera Investment Advisers purchased a new position in shares of Novartis in the second quarter valued at $241,000. Bartlett & Co. LLC grew its position in shares of Novartis by 1.6% in the third quarter. Bartlett & Co. LLC now owns 473,081 shares of the company’s stock valued at $40,614,000 after purchasing an additional 7,249 shares in the last quarter. Capital Bank & Trust Co boosted its stake in Novartis by 5.5% during the third quarter. Capital Bank & Trust Co now owns 138,207 shares of the company’s stock valued at $11,865,000 after buying an additional 7,201 shares during the period. Cedar Hill Associates LLC bought a new stake in Novartis during the third quarter valued at $248,000. Finally, Steward Partners Investment Advisory LLC bought a new stake in Novartis during the third quarter valued at $1,245,000. Institutional investors own 10.85% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “UBS Group Reiterates Neutral Rating for Novartis (NVS)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.com-unik.info/2018/01/17/ubs-group-reiterates-neutral-rating-for-novartis-nvs.html.

Novartis Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit